First Light Asset Management LLC Acquires 29,807 Shares of Oxford Immunotec Global PLC (OXFD)

First Light Asset Management LLC grew its holdings in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 5.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 626,585 shares of the company’s stock after purchasing an additional 29,807 shares during the quarter. Oxford Immunotec Global makes up 1.7% of First Light Asset Management LLC’s portfolio, making the stock its 19th biggest position. First Light Asset Management LLC owned 2.42% of Oxford Immunotec Global worth $7,801,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Quantitative Systematic Strategies LLC bought a new stake in shares of Oxford Immunotec Global in the 1st quarter valued at about $177,000. Jefferies Group LLC bought a new stake in shares of Oxford Immunotec Global in the 4th quarter valued at about $273,000. JPMorgan Chase & Co. raised its holdings in shares of Oxford Immunotec Global by 258.0% in the 1st quarter. JPMorgan Chase & Co. now owns 19,554 shares of the company’s stock valued at $243,000 after purchasing an additional 14,092 shares in the last quarter. Elkfork Partners LLC bought a new stake in shares of Oxford Immunotec Global in the 4th quarter valued at about $358,000. Finally, Trexquant Investment LP raised its holdings in shares of Oxford Immunotec Global by 158.7% in the 1st quarter. Trexquant Investment LP now owns 38,064 shares of the company’s stock valued at $474,000 after purchasing an additional 23,353 shares in the last quarter. Institutional investors and hedge funds own 91.75% of the company’s stock.

Several research analysts recently commented on the stock. BidaskClub upgraded shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Friday, February 23rd. ValuEngine lowered shares of Oxford Immunotec Global from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Zacks Investment Research upgraded shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research note on Friday, March 9th. Finally, BTIG Research set a $19.00 price objective on shares of Oxford Immunotec Global and gave the stock a “buy” rating in a research note on Tuesday, May 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $17.40.



In related news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 1st. The shares were sold at an average price of $12.77, for a total transaction of $38,310.00. Following the completion of the transaction, the director now owns 18,000 shares in the company, valued at approximately $229,860. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 6.61% of the company’s stock.

NASDAQ OXFD opened at $13.67 on Thursday. The company has a debt-to-equity ratio of 0.38, a current ratio of 5.60 and a quick ratio of 5.04. The company has a market cap of $364.67 million, a P/E ratio of -10.05 and a beta of -0.28. Oxford Immunotec Global PLC has a 52 week low of $10.00 and a 52 week high of $19.51.

Oxford Immunotec Global (NASDAQ:OXFD) last posted its quarterly earnings data on Tuesday, May 1st. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.05. The firm had revenue of $21.37 million during the quarter, compared to analyst estimates of $20.96 million. Oxford Immunotec Global had a negative net margin of 34.13% and a negative return on equity of 43.51%. Oxford Immunotec Global’s revenue was down .7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.36) EPS. research analysts forecast that Oxford Immunotec Global PLC will post -0.98 earnings per share for the current fiscal year.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply